Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Weight loss injections will be available at GP surgeries in England - but only for patients who meet strict eligibility ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced ...

Participants in the 72-week STEP UP trial who received the increased Wegovy dose of 7.2 mg experienced a mean weight reduction of 21%, while a third of them reached 25% body weight loss. Adults with ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...